Justin Martello, MD
Neurology · Newark, DENPI 1255622676
Payments from drug & device makers
Across 800 payments — averaging $844.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$142K
- AbbVie$135K
- Eli Lilly$94K
- Acadia Pharmaceuticals Inc$84K
- Amneal Pharmaceuticals LLC$71K
- Neurocrine Biosciences, Inc.$54K
- plus $94K from 27 others
Across 4 payments — averaging $1269.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
- Amneal Pharmaceuticals LLC$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 138 | $142,106 |
| AbbVie(2 entities) | 192 | $135,181 |
| Eli Lilly | 4 | $94,339 |
| Acadia Pharmaceuticals Inc | 108 | $83,829 |
| Amneal Pharmaceuticals LLC | 59 | $71,350 |
| Neurocrine Biosciences, Inc. | 86 | $54,020 |
| Acorda Therapeutics, Inc | 35 | $28,685 |
| Lundbeck LLC | 31 | $23,494 |
| MDD US Operations, LLC | 27 | $14,672 |
| UCB SA | 1 | $6,550 |
| Kyowa Kirin, Inc. | 9 | $5,732 |
| Insightec,inc | 37 | $4,793 |
| Boston Scientific | 14 | $2,628 |
| H. Lundbeck A S | 2 | $1,500 |
| Avion Pharmaceuticals | 1 | $1,460 |
| Sunovion Pharmaceuticals Inc. | 9 | $1,371 |
| Abbott | 12 | $1,180 |
| Medtronic(2 entities) | 11 | $955 |
| UCB, Inc. | 3 | $504 |
| Merz North America, Inc. | 3 | $226 |
| Dr.reddy's Laboratories,inc. | 1 | $179 |
| Merz Pharmaceuticals, LLC | 2 | $86 |
| Jazz Pharmaceuticals Inc. | 3 | $81 |
| Adamas Pharmaceuticals, Inc. | 2 | $67 |
| Supernus Pharmaceuticals, Inc. | 2 | $56 |
| Neurelis, Inc. | 1 | $35 |
| AstraZeneca | 1 | $24 |
| Livanova USA, Inc. | 1 | $23 |
| CSL Behring | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $14 |
| Cala Health, Inc. | 1 | $13 |
| Akcea Therapeutics, Inc. | 1 | $11 |
How this compares
$675,203 in reported general payments places this provider in the 95th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Newark
- Jason SilversteenNewark$2M
- Richard FischerNewark$22K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
- John PollardNewark$7K
- Shilpa KautaNewark$7K
- Brian OommenNewark$2K
- Huijun WangNewark$1K
- Muhammad AfzalNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.